AD/PD™ 2026
GemPharmatech will be attending AD/PD™ 2026, where we look forward to engaging with the neuroscience research community to discuss advanced preclinical solutions for neurodegenerative disease studies.
Our integrated platforms are designed to support mechanistic research, drug efficacy evaluation, and translational development across Alzheimer’s disease, Parkinson’s disease, and related neurological disorders.
Time: March 17–21, 2026
Location: Bella Center Copenhagen, Copenhagen, Denmark
Join us at Booth #76 and connect with our team members, including Dr. Brandy Wilkinson, Dr. Rikki Feng, Oliver Dong and Elaine Rong. They will be ready to walk you through the data, learn about your projects, and explore how our neuroscience research platform can help accelerate your discoveries.
Poster Presentations
Construction And Pharmacological Evaluation Of A New Parkinson’s Disease Mouse Model
Time: March 17, 07:30 a.m. – March 19, 12:00 p.m.
Board #: SHIFT 01-007
Listen to the poster overview [Audio Only]
Unveiling FAD3T: A Groundbreaking Transgenic Mouse Model for Accelerating Alzheimer’s Disease Research
Time: March 17, 07:30 a.m. – March 19, 12:00 p.m.
Board #: SHIFT 01-603
Listen to the poster overview [Audio Only]
Let’s Connect in Advance
Schedule a meeting with us to discuss how our integrated preclinical solutions can support your research and drug development programs.
Email: sales@gempharmatech.com
Our Neurological Capabilities
Comprehensive suite of behavioral testing services
In vivo drug efficacy evaluation platforms
End-to-end study design and execution strategies
Mechanistic research support for CNS disorders